These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 2404820)

  • 41. Prodrugs: a challenge for the drug development.
    Zawilska JB; Wojcieszak J; Olejniczak AB
    Pharmacol Rep; 2013; 65(1):1-14. PubMed ID: 23563019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
    McCart JA; Puhlmann M; Lee J; Hu Y; Libutti SK; Alexander HR; Bartlett DL
    Gene Ther; 2000 Jul; 7(14):1217-23. PubMed ID: 10918490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody-directed enzyme prodrug therapy.
    Connors TA
    Cancer Cells; 1990 Feb; 2(2):56-7. PubMed ID: 2397145
    [No Abstract]   [Full Text] [Related]  

  • 44. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ; Niculescu-Duvaz I
    Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line.
    Trinh QT; Austin EA; Murray DM; Knick VC; Huber BE
    Cancer Res; 1995 Nov; 55(21):4808-12. PubMed ID: 7585511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthetic Tuning of Domain Stoichiometry in Nanobody-Enzyme Megamolecules.
    Metcalf KJ; Kimmel BR; Sykora DJ; Modica JA; Parker KA; Berens E; Dai R; Dravid VP; Werb Z; Mrksich M
    Bioconjug Chem; 2021 Jan; 32(1):143-152. PubMed ID: 33301672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
    Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
    J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
    Aldughaim MS; Alsaffar F; Barker MD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activation of prodrugs by targeted enzymes.
    Hellström KE; Senter PD
    Eur J Cancer; 1991; 27(11):1342-3. PubMed ID: 1835844
    [No Abstract]   [Full Text] [Related]  

  • 50. Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors.
    Huber BE; Richards CA; Austin EA
    Ann N Y Acad Sci; 1994 May; 716():104-14; discussion 140-3. PubMed ID: 8024189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate.
    Wallace PM; Senter PD
    Bioconjug Chem; 1991; 2(5):349-52. PubMed ID: 1790175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD; Sharma SK; Begent RH
    Expert Opin Biol Ther; 2004 Nov; 4(11):1777-89. PubMed ID: 15500406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
    Lehouritis P; Stanton M; McCarthy FO; Jeavons M; Tangney M
    J Control Release; 2016 Jan; 222():9-17. PubMed ID: 26655063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy.
    Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2002 Nov; 269(1-2):269-81. PubMed ID: 12379367
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
    Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
    J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
    Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
    Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate.
    Bignami GS; Senter PD; Grothaus PG; Fischer KJ; Humphreys T; Wallace PM
    Cancer Res; 1992 Oct; 52(20):5759-64. PubMed ID: 1356620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
    Dore-Savard L; Chen Z; Winnard PT; Krishnamachary B; Raman V; Black ME; Bhujwalla ZM
    Anticancer Res; 2017 May; 37(5):2195-2200. PubMed ID: 28476782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.
    de Groot FM; Damen EW; Scheeren HW
    Curr Med Chem; 2001 Jul; 8(9):1093-122. PubMed ID: 11472243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.